Advertisement

Topics

FibroGen Receives Orphan Drug Designation from the FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

09:09 EDT 16 Apr 2019 | Speciality Pharma Journal

SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD).   …

Original Article: FibroGen Receives Orphan Drug Designation from the FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

NEXT ARTICLE

More From BioPortfolio on "FibroGen Receives Orphan Drug Designation from the FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...